Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer

Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer

Background The discovery of checkpoint inhibitors towards cytotoxic T-lymphocyte protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) has been revolutionary for the treatment of cancers. These therapies have only offered an average of 20%–30% response rates across the tumor spectrum and the...

Full description

Bibliographic Details
Main Authors: Bin Li, Jinping Zhang, Tao Wang, Yuhua Huang, Yifeng Xu, Chao Wang, Tianhang Zhai, Weifeng Huang, Zhijun Yuan, Shuang Dai, Shaogang Peng, Tuling Pang, Wenchao Jiang, Yuefeng Zou, Yingda Xu, Joanne Sun, Xinjiang Gong, Andy Tsun, Xiaoniu Miao
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/6/e002131.full

Internet

https://jitc.bmj.com/content/9/6/e002131.full

Similar Items